Taking antiretrovirals to prevent HIV infection mostly still involves swallowing one or more pills a day. Some long-acting products that work for a month or two at a time have been approved but are not yet in wide use in South Africa. As delegates gathered for the 25th International AIDS Conference (AIDS 2024) last week, Elri Voigt takes stock of the latest developments in this fast-moving field.
An HIV prevention injection that provides six months of protection per shot has been shown to be highly effective in a pivotal trial largely conducted in South Africa. There are however some concerns as to when the injection will become available and how widely. Thabo Molelekwa and Marcus Low report.
HIV prevention injections have been registered for use in South Africa, but their high price and limited supply means that for the next few years, while awaiting more affordable generics, very few people will be able to get the jabs. In this Spotlight special briefing, Catherine Tomlinson looks at the difficult choices facing the country if we want to offer the injection to more people more quickly. The calls we make could have global implications.
Professor Ntobeko Ntusi may be softspoken, but he is not afraid to stand by his strongly held views. As he is set to take up the hot-seat at the country’s primary health research funder, he tells Spotlight’s Biénne Huisman about his background and his priorities for the new job.
Condom distribution in South Africa has dropped dramatically over the last five years, finds a Spotlight analysis of data recently published in the Health System Trust’s District Health Barometer.
Over the last four years South Africa has taken large strides in making HIV prevention pills available at public sector clinics, but uptake has not been as good as some may have hoped. Thabo Molelekwa asks several experts why this might be.
Inside Professor Linda-Gail Bekker’s office a bookshelf is stacked with titles on general medicine, HIV and tuberculosis. Against the bookshelf, a mannequin leans dressed in a white doctor’s coat, sparkling tiara and pink Venetian mask, with a stethoscope protruding from her pocket. Known to colleagues as LGB, Bekker is one of South Africa’s top HIV researchers. Biénne Huisman chatted to Bekker about her remarkable career, finding new ways to reach young people, her love of both art and science and the thinking behind the slogan “get ripped, get prepped”.
Top South African HIV clinicians are setting their sights on different approaches to finding an HIV vaccine after the “disappointing” news that the Mosaico trial was stopped early because the vaccine did not show any efficacy. The search for an HIV jab now seems set to pivot from vaccines that induce T-cell immunity to ones that induce B-cell immunity. Adele Baleta unpacks what that means and the reasoning behind it.
HIV prevention pills are becoming more widely available in South Africa and the country is set to soon start piloting the use of an HIV prevention injection. But merely having these tools available in clinics and other places does not mean people will use them. Thabo Molelekwa asked several experts what behaviour change communications should look like in this new era of HIV prevention.
South Africa is expected to begin piloting the HIV prevention injection early next year as one of several projects that experts hope will reveal the answers to some of the biggest questions about the future of the shot – who will deliver the injection, where, and how to sell people on the idea that just six shots a year could protect them from HIV. Laura Lopez Gonzalez reports.
It is estimated that in 2021, around 0.3% of sexually active people in the Western Cape were taking antiretroviral medicines to prevent HIV infection. This is substantially lower than the national estimate of 1%. Elsabé Brits asks why uptake in the Western Cape is lagging behind most other provinces.
New child-friendly formulations of several important antiretroviral medicines were recently approved by the South African Health Products Regulatory Authority. Thabo Molelekwa asks what this means for children living with HIV in South Africa and how long it will take for these medicines to become widely available.
